- Home
- EQX vs NVAX Comparison
EQX vs NVAX Comparison
Compare EQX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | NVAX |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 1.6B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | EQX | NVAX |
|---|---|---|
| Price | $14.80 | $10.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $17.00 | $11.33 |
| AVG Volume (30 Days) | ★ 7.7M | 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.15 | N/A |
| P/E Ratio | $137.41 | ★ $3.91 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $5.59 | $5.01 |
| 52 Week High | $18.96 | $11.85 |
Technical Indicators
Market Signals| Indicator | EQX | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 55.12 |
| Support Level | $14.58 | $7.81 |
| Resistance Level | $15.06 | $10.42 |
| Average True Range (ATR) | 0.82 | 0.73 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 6.85 | 36.18 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.